Replies to post #187206 on Biotech Values

[DewDiligence]

The MRK-Hanwha deal for an Enbrel FoB was inked in 2011 (#msg-64164954), when MRK paid Hanwha $720M (#msg-64193403).

In 2013, when MRK signed on to join the Samsung-BIIB FoB venture (#msg-84781042), there were reports that the MRK-Hanwha deal had been terminated, but these reports were evidently false.

I will update the “FoB Collaborations” table in the iBox accordingly.

[DewDiligence]

Hanwha’s Enbrel FoB collaboration evidently with Merck KGaA (not MRK)—i.e. Gabi Online got the story wrong:

http://news.mk.co.kr/english/newsRead.php?sc=30800006&cm=English%20News_&year=2015&no=72951&selFlag=&relatedcode=&wonNo=&sID=308

South Korea-based drugmaker Hanwha Chemical will license out its biosimilar of an arthritis drug Enbrel to a German multinational pharmaceutical firm, Merck KGaA.

…Hanhwa had a bitter experience, in which it went into partnership with US-based Merck Sharp & Dohme [i.e. MRK] in 2011 but received a notice of cancellation of contract in the following year. …the contract was cancelled because of MSD’s revision of business strategy for biosimilar.

H/t @biosimilarz.

[oncologydoc]

This GaBi article has referenced the wrong company. The agreement is not with Merck & Co. Is is with Merck KGaA (Merck Serono)
http://news.mk.co.kr/english/newsRead.php?sc=30800006&cm=English%20News_&year=2015&no=72951&selFlag=&relatedcode=&wonNo=&sID=308